Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William P. Levin is active.

Publication


Featured researches published by William P. Levin.


British Journal of Cancer | 2005

Proton beam therapy

William P. Levin; Hanne M. Kooy; Jay S. Loeffler; Thomas F. DeLaney

Conventional radiation therapy directs photons (X-rays) and electrons at tumours with the intent of eradicating the neoplastic tissue while preserving adjacent normal tissue. Radiation-induced damage to healthy tissue and second malignancies are always a concern, however, when administering radiation. Proton beam radiotherapy, one form of charged particle therapy, allows for excellent dose distributions, with the added benefit of no exit dose. These characteristics make this form of radiotherapy an excellent choice for the treatment of tumours located next to critical structures such as the spinal cord, eyes, and brain, as well as for paediatric malignancies.


Medical Dosimetry | 2001

Comparative treatment planning between proton and X-ray therapy in pancreatic cancer.

Diana C. Hsiung-Stripp; J McDonough; Holly M. Masters; William P. Levin; Stephen M. Hahn; Heather Jones; James M. Metz

With the utilization of new biologic agents and experimental chemotherapy in the treatment of pancreatic cancer, the issue of local-regional control will become increasingly important. This study was undertaken to determine the feasibility of dose escalation using proton therapy, as compared to conventional 3-dimensional conformal radiation, by minimizing the dose to normal tissues. The photon treatment plans of 4 patients with unresectable pancreatic cancer treated on a biologic therapy trial were utilized. Each patient was treated using a 3- or 4-field photon plan with 45 Gy to the clinical target volume (CTV), followed by a boost of 14.4 Gy to the gross target volume (GTV). Using a Helax treatment planning system, proton plans were generated to encompass the same CTV and GTV to the same prescribed dose. Dose-volume histograms (DVHs) were generated for the GTV, CTV, spinal cord, liver, and right and left kidneys. Each DVH was compared between the photon and proton plans. Proton plans utilized either a 2- or 3-field technique. Available energies included 130 or 180 MeV. Range modulators and bolus were used as needed to conform to the target volume. With the CTV and GTV receiving the same dose from the proton and photon plans, all individual proton plans were superior to the photon plans in reduction of normal tissue dose. For the 4 patients, the average dose reduction to 50% of the organ at risk was 78% to spinal cord (p = 0.003), 73% to left kidney (p = 0.025), 43% to right kidney (p = 0.059), and 55% to liver (p = 0.061). These comparative treatment plans show proton therapy results in significant reductions of dose to normal tissue compared to conventional photons while treating the same target volumes. This allows for the design of dose-escalation protocols using protons in combination with new biologic therapies and chemotherapy.


International Journal of Radiation Oncology Biology Physics | 2013

Agreement Among RTOG Sarcoma Radiation Oncologists in Contouring Suspicious Peritumoral Edema for Preoperative Radiation Therapy of Soft Tissue Sarcoma of the Extremity

Houda Bahig; David Roberge; Walter R. Bosch; William P. Levin; Ivy A. Petersen; Michael G. Haddock; Carolyn R. Freeman; Thomas F. DeLaney; Ross A. Abrams; Daniel J. Indelicato; Elizabeth H. Baldini; Ying J. Hitchcock; David G. Kirsch; Kevin R. Kozak; Aaron H. Wolfson; Dian Wang

PURPOSE Peritumoral edema may harbor sarcoma cells. The extent of suspicious edema (SE) included in the treatment volume is subject to clinical judgment, balancing the risk of missing tumor cells with excess toxicity. Our goal was to determine variability in SE delineation by sarcoma radiation oncologists (RO). METHODS AND MATERIALS Twelve expert ROs were provided with T1 gadolinium and T2-weighted MR images of 10 patients with high-grade extremity soft-tissue sarcoma. Gross tumor volume, clinical target volume (CTV)3cm (3 cm longitudinal and 1.5 cm radial margin), and CTV2cm (2 cm longitudinal and 1 cm radial margin) were contoured by a single observer. Suspicious peritumoral edema, defined as abnormal signal on T2 images, was independently delineated by all 12 ROs. Contouring agreement was analyzed using the simultaneous truth and performance level estimation (STAPLE) algorithm and kappa statistics. RESULTS The mean volumes of GTV, CTV2cm, and CTV3cm were, respectively, 130 cm(3) (7-413 cm(3)), 280 cm(3) and 360 cm(3). The mean consensus volume computed using the STAPLE algorithm at 95% confidence interval was 188 cm(3) (24-565 cm(3)) with a substantial overall agreement corrected for chance (mean kappa = 0.71; range: 0.32-0.87). The minimum, maximum, and mean volume of SE (excluding the GTV) were 4, 182, and 58 cm(3) (representing a median of 29% of the GTV volume). The median volume of SE not included in the CTV2cm and in the CTV3cm was 5 and 0.3 cm(3), respectively. There were 3 large tumors with >30 cm(3) of SE not included in the CTV3cm volume. CONCLUSION Despite the fact that SE would empirically seem to be a more subjective volume, a substantial or near-perfect interobserver agreement was observed in SE delineation in most cases with high-grade soft-tissue sarcomas of the extremity. A median of 97% of the consensus SE is within the CTV2cm (99.8% within the CTV3cm). In a minority of cases, however, significant expansion of the CTVs is required to cover SE.


Journal of Surgical Oncology | 2016

Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.

Brian C. Baumann; S. Nagda; James D. Kolker; William P. Levin; Kristy L. Weber; Abigail T. Berman; Arthur P. Staddon; Lee Hartner; Stephen M. Hahn; Eli Glatstein; Charles B. Simone

Oligometastatic sarcoma pulmonary metastases (PM) are typically treated with resection and/or chemotherapy. We hypothesize that stereotactic body radiotherapy (SBRT) can be an alternative to surgery that can achieve high rates of local control (LC) with limited toxicity.


Radiotherapy and Oncology | 2016

Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment

Jennifer Vogel; Abigail T. Berman; Liyong Lin; Taine T. Pechet; William P. Levin; Peter Gabriel; Sami Khella; Sunil Singhal; John K. Kucharczuk; Charles B. Simone

BACKGROUND AND PURPOSE Radiation is an important modality in treatment of thymic tumors. However, toxicity may reduce its overall benefit. We hypothesized that double-scattering proton beam therapy (DS-PT) can achieve excellent local control with limited toxicity in patients with thymic malignancies. METHODS AND MATERIALS Patients with thymoma or thymic carcinoma treated with DS-PT between 2011 and 2015 were prospectively analyzed for toxicity and patterns of failure on an IRB-approved study. RESULTS Twenty-seven consecutive patients were evaluated. Patients were a median of 56 years and had thymoma (85%). They were treated with definitive (22%), salvage (15%) or adjuvant (63%) DS-PT to a median of 61.2/1.8 Gy [CGE]. No patient experienced grade ⩾3 toxicity. Acute grade 2 toxicities included dermatitis (37%), fatigue (11%), esophagitis (7%), and pneumonitis (4%). Late grade 2 toxicity was limited to a single patient with chronic dyspnea. At a median follow-up of 2 years, 100% local control was achieved. Three-year regional control, distant control, and overall survival rates were 96% (95% CI 76-99%), 74% (95% CI 41-90%), and 94% (95% CI 63-99%), respectively. CONCLUSIONS This is the first cohort and prospective series of proton therapy to treat thymic tumors, demonstrating low rates of early toxicity and excellent initial outcomes.


Cancer | 2017

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer

Jean-Claude M. Rwigema; Vivek Verma; Liyong Lin; Abigail T. Berman; William P. Levin; Tracey L. Evans; Charu Aggarwal; Ramesh Rengan; Corey Langer; Roger B. Cohen; Charles B. Simone

Existing data supporting the use of proton‐beam therapy (PBT) for limited‐stage small cell lung cancer (LS‐SCLC) are limited to a single 6‐patient case series. This is the first prospective study to evaluate clinical outcomes and toxicities of PBT for LS‐SCLC.


Clinical Lung Cancer | 2017

First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non–Small-Cell Lung Cancer

Jill Remick; Caitlin A. Schonewolf; Peter Gabriel; Abigail Doucette; William P. Levin; John C. Kucharczuk; Sunil Singhal; Taine T. Pechet; Ramesh Rengan; Charles B. Simone; Abigail T. Berman

Background and Purpose The characteristic Bragg peak of proton beam therapy (PBT) allows for sparing normal tissues beyond the tumor volume that may allow for decreased toxicities associated with postoperative radiation therapy (PORT). Here we report the first institutional experience with proton therapy for PORT in patients with non–small‐cell lung cancer (NSCLC) and assess early toxicities and outcomes. Materials and Methods We identified 61 consecutive patients treated from 2011 to 2014 who underwent PORT for locally advanced NSCLC for positive microscopic margins and/or positive N2 lymph nodes (stage III), with 27 patients receiving PBT and 34 receiving intensity‐modulated radiation therapy (IMRT). Results Median follow‐up time was 23.1 months for PBT (2.3‐42.0 months) and 27.9 months for IMRT (0.5‐87.4 months). The median radiation dose was 50.4 Gy for PBT (50.4‐66.6 Gy) and 54 Gy for IMRT (50.0‐72.0 Gy). Grade 3 radiation esophagitis was observed in 1 and 4 patients in the PBT and IMRT groups, respectively. Grade 3 radiation pneumonitis was observed in 1 patient in each cohort. Dosimetric analysis revealed a significant decrease in the V5 and mean lung dose (P = .001 and P = .045, respectively). One‐year median overall survival and local recurrence‐free survival were 85.2% and 82.4% (95% confidence interval, 72.8%‐99.7% and 70.5%‐96.2%, P = .648) and 92.3% and 93.3% (82.5%‐100%, 84.8%‐100%, P = .816) for PBT and IMRT cohorts, respectively. Conclusions Postoperative PBT in NSCLC is well‐tolerated and has similar excellent short‐term outcomes when compared with IMRT. Longer follow‐up is necessary to determine if PBT has a meaningful improvement over IMRT for PORT. Micro‐Abstract We investigated the survival outcomes and early toxicity profile of postoperative radiation therapy with proton beam therapy (PBT) versus intensity‐modulated radiation therapy (IMRT) for non–small‐cell lung cancer (NSCLC) in a cohort of 61 patients with positive microscopic margins and/or positive N2 lymph nodes. We found that postoperative PBT in locally advanced NSCLC is well‐tolerated and has similar excellent short‐term outcomes when compared with IMRT.


Clinical Lung Cancer | 2017

Effect of Prophylactic Cranial Irradiation on Overall Survival in Metastatic Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

Sonam Sharma; Matthew T. McMillan; Abigail Doucette; Roger B. Cohen; Abigail T. Berman; William P. Levin; Charles B. Simone; Jacob E. Shabason

Micro‐Abstract The role of prophylactic cranial irradiation (PCI) in metastatic small‐cell lung cancer (SCLC) is controversial. Using the National Cancer Database we show that patients treated with PCI have improved survival outcomes. In light of conflicting randomized trials, this study adds information to help guide physician and patient decision‐making about the utility of PCI in metastatic SCLC. Introduction Patients with small‐cell lung cancer (SCLC) have a high incidence of occult brain metastases and are often treated with prophylactic cranial irradiation (PCI). Despite a small survival advantage in some studies, the role of PCI in extensive stage SCLC remains controversial. We used the National Cancer Database to assess survival of patients with metastatic SCLC treated with PCI. Patients and Methods Metastatic SCLC patients without brain metastases were identified. To minimize treatment selection bias, patients with an overall survival (OS) < 6 months were excluded. Cox regression identified variables associated with OS. Patients were propensity score‐matched on factors associated with receipt of PCI or OS. The effect of PCI on OS was examined using Kaplan–Meier estimates. Results In the overall cohort (n = 4257), treatment with PCI (n = 473) was associated with improved survival (hazard ratio, 0.66; 95% confidence interval, 0.60‐0.74; P < .0001). Comparisons of propensity score‐matched cohorts revealed a significant survival benefit for patients who received PCI in median OS (13.9 vs. 11.1 months; P < .0001), as well as 1‐ and 2‐year OS (61.2% vs. 44.0% and 19.8% vs. 11.5%, respectively; P < .0001). This survival benefit persisted even after excluding patients who survived < 9 months (median: 15.3 vs. 12.9 months; P < .0001). In multivariable analysis, predictors of receipt of PCI were Caucasian race, younger age, and lower Charlson–Deyo score. Conclusion Using a modern population‐based data set, we showed that metastatic SCLC patients treated with PCI have significantly improved OS. This large retrospective study helps address the conflicting prospective data.


Sarcoma | 2017

Predictors of Wound Complications following Radiation and Surgical Resection of Soft Tissue Sarcomas

Drake G. LeBrun; David M. Guttmann; Jacob E. Shabason; William P. Levin; Stephen J. Kovach; Kristy L. Weber

Wound complications represent a major source of morbidity in patients undergoing radiation therapy (RT) and surgical resection of soft tissue sarcomas (STS). We investigated whether factors related to RT, surgery, patient comorbidities, and tumor histopathology predict the development of wound complications. An observational study of patients who underwent STS resection and RT was performed. The primary outcome was the occurrence of any wound complication up to four months postoperatively. Significant predictors of wound complications were identified using multivariable logistic regression. Sixty-five patients representing 67 cases of STS were identified. Median age was 59 years (range 22–90) and 34 (52%) patients were female. The rates of major wound complications and any wound complications were 21% and 33%, respectively. After adjusting for radiation timing, diabetes (OR 9.6; 95% CI 1.4–64.8; P = 0.02), grade ≥2 radiation dermatitis (OR 4.8; 95% CI 1.2–19.2; P = 0.03), and the use of 3D conformal RT (OR 4.6; 95% CI 1.1–20.0; P = 0.04) were associated with an increased risk of any wound complication on multivariable analysis. These data suggest that radiation dermatitis and radiation modality are predictors of wound complications in patients with STS.


Radiotherapy and Oncology | 2017

A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma

David M. Guttmann; Melissa A. Frick; Ruben Carmona; Curtiland Deville; William P. Levin; Abigail T. Berman; Chidambaram Chinniah; Stephen M. Hahn; John P. Plastaras; Charles B. Simone

BACKGROUND AND PURPOSE Proton reirradiation for sarcoma has not been previously described. We hypothesized that this strategy would provide favorable toxicity and survival outcomes. MATERIAL AND METHODS Patients with soft tissue sarcoma in a previously-irradiated field were enrolled on a prospective trial of proton reirradiation. The primary endpoint was provider-reported acute toxicity. Secondary endpoints included late toxicities, local control, and overall survival. RESULTS 23 patients underwent proton reirradiation. Median time between radiation courses was 40.7months (range 10-272). No grade 4-5 toxicities were observed. One patient (4%) experienced acute grade 3 dysphagia. Common grade 2 acute toxicities were fatigue (26%), anorexia (17%), and urinary incontinence (13%). There were two grade 3 late wound infections (10%) and one grade 3 late wound complication (5%). Grade 2 late complications included lymphedema (10%), fracture (5%), and fibrosis (5%). At a median follow-up of 36months, the 3-year cumulative incidence of local failure was 41% (95% CI [20-63%]). Median overall survival and progression-free survival were 44 and 29months, respectively. In extremity patients, amputation was spared in 7/10 (70%). CONCLUSIONS Proton reirradiation of recurrent/secondary soft tissue sarcomas is well tolerated. While longer follow-up is needed, early survival outcomes in this high-risk population are encouraging.

Collaboration


Dive into the William P. Levin's collaboration.

Top Co-Authors

Avatar

Charles B. Simone

University of Maryland Medical Center

View shared research outputs
Top Co-Authors

Avatar

Abigail T. Berman

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Stephen M. Hahn

University of Texas MD Anderson Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Ramesh Rengan

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Keith A. Cengel

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

E.P. Xanthopoulos

Columbia University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. Heskel

Hospital of the University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar

Melissa A. Frick

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge